NeuroPace Raises 2025 Revenue Guidance to $94-98 Million on Strong RNS System Sales.

NeuroPace has raised its 2025 revenue guidance to $94-98 million, driven by strong sales of its RNS system for neurological conditions. The company has also completed a debt refinancing, enhancing its financial flexibility to support growth and expansion. This move is expected to provide NeuroPace with the necessary resources to continue its growth trajectory and expand its market presence.

Mountain View, Calif., July 2, 2025 — NeuroPace, Inc. (Nasdaq: NPCE), a leading medical device company focused on transforming the lives of people living with epilepsy, has announced an increase in its 2025 revenue guidance to between $94 million and $98 million. This significant revision is driven by robust sales of its RNS System, a brain-responsive platform designed to deliver personalized, real-time treatment at the seizure source. Additionally, the company has completed a debt refinancing, securing a $75 million credit facility with MidCap Financial at favorable terms. This move aims to enhance NeuroPace's financial flexibility, enabling it to support growth and expansion initiatives.

The company's second-quarter 2025 financial results highlighted a 22% year-over-year revenue growth to $23.5 million, with RNS System revenue growing 21% in the first half of 2025 compared to the same period in 2024. Gross margin for the quarter reached 77.1%, driven by manufacturing efficiencies and a positive product mix. The company also reported a strong operational performance, with a gross margin guidance of between 75% and 76% for the full year 2025, up from previous guidance of 73% and 75%.

NeuroPace's strategic and operational highlights for the quarter include compelling one-year preliminary data from the NAUTILUS study, which demonstrated a statistically significant safety profile but did not reach statistical significance on the primary effectiveness endpoint. However, the study showed statistically significant and clinically meaningful improvement across multiple secondary effectiveness endpoints, including a 79% median GTC seizure reduction at 12 months. The company also achieved record highs in the number of active accounts and prescribers and received a favorable outcome in CMS's FY 2026 Inpatient Prospective Payment System (IPPS) final rule, which preserved reimbursement stability for Medicare patients.

The debt refinancing will provide NeuroPace with the necessary resources to continue its growth trajectory and expand its market presence. The company's CEO, Joel Becker, stated, "We are pleased with the continued momentum in our business through the second quarter of 2025, as we made significant progress across a number of key initiatives to position NeuroPace for sustained long-term growth. We are advancing our strategy, driving increased access to and adoption of RNS therapy and supporting operating leverage as we scale."

NeuroPace will host a conference call to discuss the second quarter 2025 financial results after market close on Tuesday, August 12, 2025, at 4:30 P.M. Eastern Time. Investors interested in listening to the conference call can access a live and archived webcast at [NeuroPace Investor Relations](https://investors.neuropace.com/news-and-events/events) or by dialing +1-877-407-3982 and referencing Conference ID 13754370.

References:
[1] https://www.biospace.com/press-releases/neuropace-reports-second-quarter-2025-financial-results-and-increases-2025-revenue-guidance